| Quantity: | |
|---|---|
Broad model portfolio – covering IgE-dependent (OVA), direct mast cell activator (C48/80) and passive sensitization (PCA) mechanisms.
Multiple species/strains – BALB/c, C57BL/6 mice and Wistar rats available.
Composite endpoint —body weight, eosinophil count, serum IgE, mast cell degranulation, paw swelling, Evans blue extravasation, histopathology (HE, toluidine blue).
Translational Value – Ideal for testing anti-IgE biologics, mast cell stabilizers, H1 antihistamines, and MRGPRX2 antagonists.
IND Ready Packet – Research can be conducted in accordance with GLP principles.
OVA-induced BALB/c urticaria model
OVA-induced C57BL/6 urticaria model
C48/80 induces BALB/c acute urticaria model
DNP-IgE and DNFB-induced BALB/c PCA model
OVA induced rat PCA model
• Efficacy testing of immunomodulators (corticosteroids, mycophenolate mofetil, cyclophosphamide) on IgAN
• Evaluation of renoprotective agents and angiotensin-converting enzyme (ACE) inhibitors
• Target validation of IgA immune complex deposition and mesangial cell activation
• Biomarker discovery (albuminuria, serum IgA levels)
• Pharmacology and toxicology studies to support IND
Model | Species/Strain | induction method | key endpoint | study time |
OVA-induced BALB/c urticaria model | BALB/c mouse | OVA + Alum Sensitization + Intradermal OVA Challenge | Body weight, eosinophils, serum IgE, mast cell degranulation, HE score | 4-6 weeks |
OVA-induced C57BL/6 urticaria model | C57BL/6 mouse | OVA + Alum Sensitization + Intradermal OVA Challenge | Mast cell degranulation, serum IgE, eosinophils | 4-6 weeks |
C48/80 induces BALB/c acute urticaria model | BALB/c mouse | Intradermal C48/80 | Paw swelling, Evans blue extravasation | 30 minutes – 24 hours |
DNP-IgE and DNFB-induced BALB/c PCA model | BALB/c mouse | Intradermal DNP-IgE + topical DNFB | Number of urticaria, itching events | 24-48 hours |
| OVA induced rat PCA model | vistar rat | Intradermal OVA Sensitization Serum + Intravenous OVA with Evans Blue | Ear thickness, Evans blue OD, mast cell degranulation | 24-48 hours |
Q: What is the difference between these urticaria models?
A: The OVA model represents IgE-dependent, Th2-mediated chronic urticaria. The C48/80 model is acute and directly activates mast cells through MRGPRX2, making it ideal for studying non-IgE-mediated pathways. The PCA model evaluates passive sensitization and is used to evaluate anti-IgE therapy.
Q: Which model is best for testing anti-IgE biologics?
A: PCA models (DNP-IgE-induced or OVA rat PCA) are well suited for evaluating anti-IgE antibodies because they directly measure IgE-mediated mast cell activation.
Q: Can these models be used for IND support studies?
Answer: Yes. Studies can be conducted according to GLP principles for regulatory submissions (FDA, EMA).
Q: Do you offer customized study protocols (e.g., different antigen doses, treatment times)?
Answer: Of course. Our scientific team tailors induction protocols, treatment plans and endpoint analyzes for your specific drug candidate.
Q: What is the typical timeline for a pilot efficacy study?
A: OVA models require 4-6 weeks; C48/80 and PCA models are acute (hours to days) allowing for rapid screening.
